An overview of the biological and clinical distinctions between hemophilia A and B, including factor deficiencies, prevalence, diagnostic nuances, and implications for treatment strategy.
Annette Von Drygalski, MD, PharmD
Advertisement
Articles by Annette Von Drygalski, MD, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI Helps Managed Care Identify High-Risk Patients Sooner and More Precisely | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
Cardiovascular, Renal and Metabolic Conditions Increasingly Prevalent, Expensive in Medicare Fee-For-Service Population | AMCP Nexus 2025
4
Real-World Data Drives CAR T Treatment Decisions, Reveals Benefits of Earlier Administration | AMCP Nexus 2025
5
